Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio. The company which focuses on developing psilocybin-based medicines for illnesses with unmet medical needs announced the 2 patents via press release. The first #63/405,786 is a patent application for the use of psilocybin to treat patients with fibromyalgia while the other patent, #63/375,305 expands the intellectual property related to the company’s development of TRP-8803. About Tryp Therapeutics Tryp Therapeutics is a cutting-edge biotechnology company that is focused on developing molecules related to psilocybin to treat diseases The post Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio appeared first on Psychedelic Chronicle.
External link. We are not responsible for the content.
Read more ↗More From Psychedelic Chronicle
Choose Ketamine Complete Capital Raise to Expand Technology Platform
In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, ha...
Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it ha...
Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has beg...
Latest News
Comment perfectionner la préparation de son trip ?
La préparation d’un voyage est un processus à la fois intérieur et extérieur – qui consiste à aligner l’intention, l’...
Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of...
The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use
Plus: RAND survey shows that nearly a quarter of U.S. adults support legal use of psilocybin mushrooms; Reunion Neuro...
Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials
In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field an...
Can Psychedelics Break the Consumption Cycle?
Consumer culture doesn’t just shape what we buy — it shapes what we want. Here’s why that’s harder to escape than you...
Psychedelics Can Just Be for Fun
Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.